Nektar Therapeutics (NKTR) Posts Q4 Loss of 33c/Share, Beats by 15c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $71.94 +0.26%
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.33), $0.15 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $15.8 million versus the consensus estimate of $12.66 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- Vivakor projects $270M in Q3 2026 revenue from crude oil marketing
- Rex American Resources Corp. (REX) Tops Q2 EPS by 64c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
